The pharmaceutical company that makes the popular obesity drug Ozempic plans to build a mega-factory in Ireland
Kyiv • UNN
Novo Nordisk plans to build an obesity drug megafactory in Ireland to create 1,100 jobs and increase production capacity.
Novo Nordisk A/S, the Danish maker of popular drugs used in the treatment of obesity Ozempic and Wegovy, plans to build a "mega manufacturing facility" outside of outside Dublin, Ireland, to meet the growing demand. This UNN writes with reference to Bloomberg.
The pharmaceutical giant has applied to build 147,192-square-meter campus that will create up to 1,100 jobs in the region, according to a Sunday Times report, which cited detailed documents submitted with the planning application.
Success Ozempic and Wegovy has transformed 100-year-old Novo Nordisk into the most valuable listed company in Europe, with a market capitalization larger than the Danish domestic economy. Demand has also tested the company's production the company's production capacity, and it's struggling to keep up.
The report said the investment is likely to exceed 2 billion euros ($5.51 billion), based on similar developments at the companies. It will take 18 to 24 months to complete and should be fully operational by 2026.
According to the Sunday Times, if approved, the project in Dublin would include three prefabrication and packaging facilities, a warehouse building, two assembly and packaging facilities, an administration building and a laboratory.
